Scrip's Deal of the year

Oxford Biomedica PLC
05 December 2007





FOR IMMEDIATE RELEASE                                            5 DECEMBER 2007


         OXFORD BIOMEDICA WINS SCRIP'S LICENSING DEAL OF THE YEAR AWARD

Oxford, UK: 5 December 2007: Oxford BioMedica (LSE: OXB), a leading gene therapy
company, announced today that its collaboration with sanofi-aventis received the
award for Licensing Deal of the Year at the Scrip Awards 2007. The Scrip Awards
recognise achievements in the global pharmaceutical and biotechnology
industries. Nick Woolf, Oxford BioMedica's SVP Corporate Strategy, collected the
award last night during the ceremony held at the Hilton Hotel in Park Lane,
London.

Oxford BioMedica and sanofi-aventis announced their collaboration in March 2007
for the global development and commercialisation of TroVax(R), Oxford
BioMedica's novel immunotherapy, for the treatment and prevention of cancers. In
choosing the winner for Scrip's Licensing Deal of the Year, the judges looked at
all aspects of the short-listed transactions, from the monetary and strategic
value to the benefits they give to both sides.

Nick Woolf said: 'We are extremely proud to have received this prestigious Scrip
Award. It is an honour to have our deal recognised in a year when so many
outstanding partnerships have been announced. This award is testament to the
hard work and dedication of the teams at Oxford BioMedica and sanofi-aventis.'

                                       -Ends-


For further information, please contact:

Oxford BioMedica plc:                                 Tel: [phone]

Professor Alan Kingsman, Chief Executive

JPMorgan Cazenove Limited:                            Tel: [phone]

James Mitford/Gina Gibson

City/Financial Enquiries:                             Tel: [phone]

Lisa Baderoon/ Mary-Jane Johnson

Buchanan Communications

Scientific/Trade Press Enquiries:                     Tel: [phone]

Gemma Price/ Holly Griffiths/ Katja Stout

College Hill Life Sciences

US Enquiries:                                         Tel: [phone]

Thomas Fechtner

The Trout Group LLC


Notes to editors


1. Oxford BioMedica

Oxford BioMedica (LSE: OXB) is a biopharmaceutical company specialising in the
development and commercialisation of novel therapeutic vaccines and gene-based
therapies with a focus on oncology and neurotherapy. The Company was established
in 1995 as a spin-out from Oxford University, and is listed on the London Stock
Exchange.


The Company has a platform of gene delivery technologies, which are based on
highly engineered viral systems. Oxford BioMedica also has in-house clinical,
regulatory and manufacturing know-how. In oncology, the lead product candidate
is TroVax(R), an immunotherapy for multiple solid cancers, which is licensed to
sanofi-aventis for global development and commercialisation. A Phase III trial
of TroVax in renal cancer is ongoing and two Phase III trials in colorectal
cancer are planned. Oxford BioMedica has two other anti-cancer product
candidates in Phase II development for melanoma and pancreatic cancer
respectively. In neurotherapy, the Company has submitted a Clinical Trial
Application to start a Phase I/II trial of its gene-based treatment for
Parkinson's disease, ProSavin(R). The neurotherapy pipeline also includes
preclinical gene-based therapeutics for vision loss, motor neuron disease and
nerve repair.


The Company is underpinned by over 80 patent families, which represent one of
the broadest patent estates in the field. The Company has a staff of
approximately 80 split between its main facilities in Oxford and its wholly
owned subsidiary, BioMedica Inc, in San Diego, California. Corporate partners
include sanofi-aventis for TroVax and Wyeth for an anti-cancer targeted antibody
therapy. The Company also has collaborations with Sigma-Aldrich, MolMed and
Virxsys. Technology licensees include Biogen Idec, Merck & Co, GlaxoSmithKline
and Pfizer.


Further information is available at www.oxfordbiomedica.co.uk



                      This information is provided by RNS
            The company news service from the London Stock Exchange